Market Newsdesk

MCLEAN, Va. and GULFPORT, Miss., March 02, 2023 (GLOBE NEWSWIRE) — HII (NYSE: HII) and Ocean Aero initiated a strategic agreement to advance the combined capabilities of their respective unmanned maritime platforms and autonomy software solutions. The unmanned solution providers recently commenced multiple, simultaneous efforts to enhance the operational reach and duration of the platforms, collaborative autonomy behaviors, shared sensor fusion and perception capabilities, and accelerated seabed-to-shore data transmission methods.

“We are pleased to partner with Ocean Aero to further expand the operational capabilities of the U.S. Armed Forces, partner nations and other maritime-focused commercial institutions,” said Duane Fotheringham, president of the Unmanned Systems business group at HII’s Mission Technologies division. “We are excited to combine the best of our individual products to deliver an exceptional suite of solutions to our customers.”

Kevin Decker, Ocean Aero chief executive officer, added: “This is the perfect time for us to partner with HII. With rising maritime challenges increasing worldwide, we need new capabilities to meet them. Incorporating our two firms’ autonomous vehicle value propositions will unlock new tools for our customers at home and abroad.”  

HII and Ocean Aero are involved in several unmanned maritime systems initiatives and exercises across the globe. Ocean Aero recently completed Digital Horizon, the U.S. Fifth Fleet Maritime Domain Awareness exercise in the Arabian Gulf, where HII’s REMUS vehicles (MK18 Mod 1 and MK18 Mod 2) have been deployed continuously since 2013. The HII-Ocean Aero team is already planning to demonstrate their combined capabilities at an upcoming event in the region, in addition to other planned events and exercises for U.S. and international partners.

HII is the preeminent unmanned underwater vehicle manufacturer and a pioneer in the UUV industry, continuously producing REMUS vehicles since the early 2000s. HII manufactures a full range of REMUS UUVs, from small to extra-large, with endurance ranging from several hours to months at depths down to 6,000 meters. More than 600 REMUS UUVs have been sold across the globe, with a majority of those still in operational use today. Additionally, HII’s Odyssey autonomy software solution offers scalable autonomy aligned with open architecture standards, including Unmanned Maritime Autonomy Architecture.

Ocean Aero pioneered the world’s first and only environmentally powered Autonomous Underwater and Surface Vehicle, the TRITON, which collects data both above and below the ocean’s surface and relays it to users from anywhere at any time. Dual modalities allow users to integrate a variety of sensor payloads and communications capabilities, expanding the ocean data collection possibilities and breaking paradigms created by manned platforms. Persistent collections and real-time data transmissions are feeding the most complex models for weather, climate and ocean health and creating transformational change in the maritime space.

About HII

HII is a global, all-domain defense provider. HII’s mission is to deliver the world’s most powerful ships and all-domain solutions in service of the nation, creating the advantage for our customers to protect peace and freedom around the world.

As the nation’s largest military shipbuilder, and with a more than 135-year history of advancing U.S. national security, HII delivers critical capabilities extending from ships to unmanned systems, cyber, ISR, AI/ML and synthetic training. Headquartered in Virginia, HII’s workforce is 43,000 strong. For more information please visit:

• HII on the web:  https://www.hii.com/
• HII on Facebook: https://www.facebook.com/TeamHII
• HII on Twitter: https://www.twitter.com/wearehii 
• HII on Instagram: https://www.instagram.com/wearehii

About Ocean Aero

Ocean Aero is headquartered in Gulfport, Mississippi, the heart of the Gulf Blue Economy. Proudly 100% made in the USA and with solely American investors, Ocean Aero is a team of nearly one hundred people who source our parts from the U.S. and our allies. Together with our partners in both academia and industry, we are committed to clean, rugged, and superior ocean data collection wherever it’s needed, whenever it’s needed. For more information please visit:

• Ocean Aero on the web: https://www.oceanaero.com
• Ocean Aero on Facebook: https://facebook.com/OceanAeroUS
• Ocean Aero on Instagram: https://www.instagram.com/oceanaeroinc

Contact:

Greg McCarthy
(202) 264-7126
[email protected]

LONDON, March 02, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three upcoming events as follows:

• Cowen 43^rd Annual Health Care Conference: ‘Neuropsych Panel’ at 12:50pm ET on March 6, 2023 and host investor meetings
• Oppenheimer 33^rd Annual Healthcare Conference: presentation at 10:00am ET on March 13, 2023 and host investor meetings
• Loop Capital Conference: host investor meetings on March 14, 2023

Live audio webcast of the panel and presentation will be accessible from the “Events” page of the Investors section of the COMPASS website. Each replay of the webcast will be accessible for 30 days following each event. For more information, please visit ir.compasspathways.com.

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). We have commenced a phase 3 clinical program of COMP360 psilocybin therapy in TRD, the largest randomised, controlled, double-blind psilocybin therapy clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also conducting phase 2 clinical studies of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the United States. Our vision is a world of mental wellbeing. www.compasspathways.com

Availability of other information about COMPASS Pathways

Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission (the “SEC”) filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Enquiries
        

Media: Amy Lawrence, [email protected], +44 7813 777 919
Investors: Stephen Schultz, [email protected], +1 401 290 7324

NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) — Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased the securities of Cognyte Software Ltd. (“Cognyte” or the “Company”) (NASDAQ: CGNT) between February 2, 2021 and June 28, 2022, both dates inclusive (the “Class Period”).

The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that Cognyte created, distributed, and provided reconnaissance tools and services that violated community standards and terms of service of communication network sources and technologies, like Facebook, exposing the Company to significant financial and reputational risk.

On December 16, 2021, Meta Platforms Inc., the parent company of Facebook and Instagram, issued a “Threat Report” which revealed that Cognyte “sells access to its platform which enables managing fake accounts across social media platforms including Facebook, Instagram, YouTube, and VKontakte (VK), and other websites to social-engineer people and collect data.” This conduct “violated multiple Community Standards and Terms of Service,” and “[g]iven the severity of their violations,” Meta disabled Cognyte’s ability to use its platforms, among other things. On this news, Cognyte’s common stock price declined more than 5%.

Then, on April 5, 2022, Cognyte revealed that it was forced to modify its solutions in response to the Threat Report. Cognyte also announced disappointing financial results and guidance. On this news, Cognyte’s common stock price declined more than 31%.

Finally, on June 28, 2022, Cognyte released its first quarter 2022 financial results which badly missed analyst estimates across the board. Analysts immediately downgraded Cognyte’s rating and reduced price targets. On this news, Cognyte’s common stock price declined more than 28%, further damaging investors.

Investors who purchased or otherwise acquired shares of Cognyte should contact the Firm prior to the May 1, 2023 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].

Please visit our website at http://www.gme-law.com for more information about the firm.

Maranello (Italy), 2 March 2023 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari”) announces that Ferrari S.p.A., its wholly-owned Italian subsidiary, has signed a multi-year partnership agreement with Virtual Gaming Worlds (VGW), a global technology Company that specializes in the creation of cutting-edge online social games.

Under the new multi-year agreement, effective from the first Formula 1 Grand Prix of the season in Bahrain (3-5 March 2023), VGW will become Premium Partner of Scuderia Ferrari.  

Ferrari Chief Racing Revenue Officer, Lorenzo Giorgetti, said: “We are pleased to announce the arrival of VGW as a Premium Partner. As leaders in the gaming technology sector, they share our passion for innovation and thinking outside the box. We look forward to working with them in offering new assets and experiences to our loyal and passionate tifosi.”

“We are excited to partner with Ferrari, one of the world’s most iconic global brands. With such a rich history, success in motorsport and a brand synonymous with winning, achievement, passion and luxury, we look forward to working together and our next chapter of growth,” VGW founder, Chairman and CEO Laurence Escalante said. “F1 is a truly global sport with massive reach that has experienced amazing growth in recent years, particularly in the US, and there’s no bigger brand than Ferrari. We may operate in different industries, but share similar beliefs when it comes to the power of technology and teams for performance, and the role of passion that unites us all.”

Attachment

• PR_VGW Partner_ENG

H
ealth
care
and med-tech
management
teams join forces to accelerate longevity-tech solutions into
more than
130 million American lives by 2030.

Norcross, Georgia, and San Antonio, Texas, March 02, 2023 (GLOBE NEWSWIRE) — Viveon Health Acquisition Corp. (NYSE American: VHAQ, VHAQW, VHAQR, VHAQU), a special purpose acquisition company led by principals experienced in healthcare and med-tech innovation, is pleased to announce that it has identified and entered into a letter of intent with a business combination target company, Clearday (OTCQX: CLRD).

Clearday provides a technology platform for the aging population that integrates numerous healthcare innovations into personalized, AI-driven care experiences, which continuously assesses an individual’s cognitive and physical capabilities. The company’s customized treatment plans are intended to improve the quality of life for aging and special needs populations. With it’s autonomous companion robotics and innovative care treatments, Clearday intends to address the $1.4 Trillion burden in annual National Health Expenditures for aging adults.

Company Overview

Clearday’s (www.myclearday.com) mission is to provide industry-leading longevity care that is more accessible and affordable. Clearday enables aging individuals, those with special needs, and their families, to optimize their quality of life across the healthcare continuum: at home, in community centers, during medical visits, and at full and part-time care facilities. Clearday’s Longevity Care Platform seamlessly integrates numerous health technology innovations into personalized AI-driven care experiences. The platform continuously assesses an individual’s cognitive and physical capabilities to deliver a customized plan.

Globally, the population of individuals over the age of 60 is projected to double by 2050, resulting in nearly 2.1 billion people. In 2035, the US Census Bureau predicts that for the first time, there will be more Americans over the age of 65 than those under 18. These demographics drive the need for new longevity-tech solutions that provide continuous monitoring, increased engagement, and proactive interventions for older individuals.

The Clearday Longevity Care Platform delivers solutions through a hub-n-spoke model involving Clearday at Home, Clearday Labs, Clearday Clubs, Clearday Residential, and Clearday Robotics. Together, they offer the industry’s leading proactive engagement, intervention, and monitoring solutions for the aging population.

Management Comments

“Clearday is an ideal merger partner for Viveon Health as it is a transformative healthcare technology company at its inflection point of rapid growth — and addresses an underserved, large, and expanding market,” said Jagi Gill, Chief Executive Officer and Chairman of Viveon Health. “As operators ourselves in the healthcare technology space, our hands-on diligence revealed the Clearday team’s deliberate expansion and acceleration of their longevity-tech business plan impacting the arc from home to residential care facilities. By leveraging its operational excellence and history in longevity care and bolting on AI-driven solutions to monitor mental and physical health, its solutions can deliver real-time engagement with individuals and their families through robotic-assisted companion care designed to deliver support at any setting. I look forward to working with Jim and the rest of the Clearday team to execute their global sales channel expansion and market development plan poised to deliver growth and shareholder value.”

James Walesa, CEO and Founder said, “We are thrilled with the opportunity to partner with Viveon and its industry-leading founders, Drs. Jagi Gill and Rom Papadopoulos. Both have decades of experience scaling healthcare technology businesses. Clearday began seeking partners with operational and financial expertise who shared the vision of Clearday’s ‘Aging in the Right Place.’ It has taken longer than I wanted, but today we found the team that combines capital markets experience with healthcare leadership to accelerate Clearday’s mission. Their extensive professional contacts and experience will bolster our sales and go-to-market initiatives and generate additional revenue opportunities for the combined companies.”

Transaction Overview

Under the terms of the letter of intent, Clearday’s existing equity holders would convert 100% of their equity into the combined public company. The proposed transaction values Clearday at $250 million. Viveon expects to announce additional details regarding the proposed business combination when a definitive merger agreement is executed.

Completion of a business combination with Clearday is subject to, among other matters, the completion of due diligence, the negotiation of a definitive agreement providing for the transaction, satisfaction of the conditions negotiated therein and approval of the transaction by the board and stockholders of both Viveon and Clearday. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all.

About
Clearday
, Inc.

Clearday^™ is an innovative longevity healthcare technology company with a modern, hopeful vision for making high-quality care solutions more accessible, affordable, and empowering for aging individuals and their families. Clearday has a decades-long experience in non-acute care through its subsidiary Clearday Living, which operates highly-rated residential memory care and adult daycare communities. Its Longevity Care Platform brings Clearday solutions to people wherever they are. Its platform is at the intersection of telehealth, remote monitoring, and patient engagement — all delivered across mobile, wearable, and robotic endpoints in a Software-as-a-Service (SaaS) and Robotics as a Service (RaaS) model. Learn more about Clearday and its pioneering legislative efforts to bring the “Innovative Cognitive Care Act for Veterans” to Congress at www.myclearday.com.

About Viveon Health Acquisition Corp.

Viveon Health Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It is the Company’s intention to pursue prospective targets that are focused on the healthcare sector in the United States and other developed countries.

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project,” “outlook” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Viveon’s ability to enter into a definitive agreement or consummate a transaction with the target company. These statements are based on various assumptions and on the current expectations of Viveon’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Viveon and the target company. These forward-looking statements are subject to a number of risks and uncertainties, including: Viveon’s ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction with the target company; the risk that the approval of the stockholders of Viveon for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction; the amount of redemption requests made by Viveon’s stockholders and the amount of funds remaining in Viveon’s trust account after satisfaction of such requests; those factors discussed in Viveon’s prospectus for its initial public offering dated December 28, 2020, under the heading “Risk Factors,” and other documents of Viveon filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Viveon presently does not know or that Viveon currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Viveon’s expectations, plans or forecasts of future events and views as of the date hereof. Viveon anticipates that subsequent events and developments will cause Viveon’s assessments to change. However, while Viveon may elect to update these forward-looking statements at some point in the future, Viveon specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Viveon’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contact:

Rom Papadopoulos
Viveon Health Acquisition Corp.
Chief Financial Officer
[email protected]
404-861-0839

Ginny Connolly
Clearday Inc.
Investor Relations
[email protected]
210-451-0839